OPEN FORUM
Since RT Image has started their blog page, I have used it as an editorial page and a place to let you know what is happening in different aspects of both radiology and the peripherals that affect it and us. Having said that, I am opening this month's dialog to you, so if here is something you would like to discuss with myself and others, here is your chance.
Your topics and questions are welcome. If there is something I can help you with, please do not hesitate to ask. Some topics may require research, so, if I take a few days to get back to you, don't be discouraged.
It is now up to you. I would like to here from you.
Ok. Let's talk about GFR and contrast guidelines for NSF. Do you have any questions regarding this?
Next: Standardized MR Protocols: Comments?
Here is a few to dwell on.
Obviously, as MR imaging is used more and more for diagnosis and management decisions, there have been some limiting factors concerning the lack a standardized protocol for how MR imaging should be used for patients with MS or suspected to have MS, also, when to use MR imaging and the minimum standard.
If you could shed any light in that direction, I'd be grateful.
A new study of people with Nephrogenic Systemic Fibrosis (NSF) has again found a strong link between the condition and the use of gadolinium contrast dyes. The study, conducted by researchers at Vanderbilt University, concludes that gadolinium contrast dyes should be used “judiciously” in patients with pre-existing kidney disease, and their benefits should be carefully weighed against their risks.
NSF is a devastating condition that affects people with pre-existing kidney problems. There is currently no cure for NSF and no one understands its specific cause. The disorder is characterized by high blood pressure, burning, itching, swelling and hardening of the skin. Other symptoms include red or dark patches on the skin; pain deep in the hip bones or ribs and muscle weakness. NSF can progress to the point of causing severe stiffness in joints, and it can lead to death.
A growing mountain of evidence has linked NSF to gadolinium contrast dyes used in MRI and MRA studies, and it is theorized that people with kidney problems may not be able to quickly eliminate gadolinium from their body. In September 2007, the Food & Drug Administration (FDA) asked the manufacturers of gadolinium contrast dyes to add a black box warning to the product labels about its association with NSF. The FDA also warned that patients with kidney disease should avoid gadolinium contrast agents.
What does this mean for my patients?